Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~37 mi. (Lausanne, Switzerland, +199 more cities)

CHUV (centre hospitalier universitaire vaudois) ( Site 0712)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~37 mi. (Lausanne, Switzerland, +144 more cities)

Centre Hospitalier Universitaire Vaudois

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

~37 mi. (Lausanne, Switzerland, +34 more cities)

CHUV (centre hospitalier universitaire vaudois) ( Site 0333)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

~37 mi. (Lausanne, Switzerland, +21 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)

Melanoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

~37 mi. (Lausanne, Switzerland, +27 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)

Melanoma

lenvatinib, +3 more drugs

immunotherapy, +1 more type

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

~37 mi. (Lausanne, Switzerland, +30 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)

Melanoma

lenvatinib, +4 more drugs

immunotherapy, +2 more types

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

~37 mi. (Lausanne, Switzerland, +24 more cities)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)

Melanoma

MK-4830, +3 more drugs

immunotherapy

A Study of SGN-B6A in Advanced Solid Tumors

~37 mi. (Lausanne, Switzerland, +10 more cities)

University Hospital Lausanne CHUV

HER2 Negative

Bladder Carcinoma, +9 more conditions

SGN-B6A

targeted therapy

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

~37 mi. (Lausanne, Switzerland)

CHUV Oncology Department

ER Negative, +2 more biomarkers

Breast Carcinoma

CMP-001, +1 more drug

immunotherapy, +2 more types

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~58 mi. (Besançon, France, +144 more cities)

CHU Jean Minjoz ( Site 1205)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~58 mi. (Besançon, France, +176 more cities)

CHU Besancon - Hopital Jean Minjoz ( Site 2068)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~58 mi. (Besançon, France, +226 more cities)

CHU Jean Minjoz ( Site 0423)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type